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doi:10.1Objective: The SynCardia Total Artificial Heart (SynCardia Systems Inc, Tucson, Ariz) has been used as
a bridge to cardiac transplantation in 930 patients worldwide and in 101 patients in our program. Our experience
with SynCardia Total Artificial Heart implantation documents its indications, safety, and efficacy.
Methods: Data regarding preoperative condition, mortality, and morbidity have been reviewed and analyzed.
Results: From January 1993 to December 2009, 101 patients had bridge to transplant procedures with the Syn-
Cardia Total Artificial Heart. Ninety-one percent of cases were Interagency Registry for Mechanically Assisted
Circulatory Support profile 1, and the remaining 9% of cases were failing medical therapy on multiple inotropic
medications. The mean support time was 87 days (median, 53 days; range, 1–441 days). Pump outputs during
support were 7 to 9 L/min. Adverse events included strokes in 7.9% of cases and take-back for hemorrhage in
24.7% of cases. Survival to transplantation was 68.3%. Causes of death of 32 patients on device support in-
cluded multiple organ failure (13), pulmonary failure (6), and neurologic injury (4). Survival after transplanta-
tion at 1, 5, and 10 years was 76.8%, 60.5%, and 41.2%, respectively. The longest-term survivor is currently
alive 16.4 years postimplantation.
Conclusions: These patients were not candidates for left ventricular assist device therapy and were expected to
die. The SynCardia Total Artificial Heart offers a real alternative for survival with a reasonable complication rate
in appropriate candidates who otherwise might have been assigned to hospice care. (J Thorac Cardiovasc Surg
2012;143:727-34)Total artificial heart (TAH) implantation as a bridge to
transplantation was attempted in 19691 and 1981.2 In
1985, we implanted the Jarvik-7 (Symbion Inc, Salt Lake
City, Utah) in a patient for the first successful bridge to
transplant followed by long-term survival.3 Since that era,
approximately 15,000 mechanical circulatory support de-
vices have been implanted in patients, including more
than 930 SynCardia Total Artificial Heart (TAH-t) (SynCar-
dia Systems Inc, Tucson, Ariz) implants worldwide. The
SynCardia TAH-t became the only TAH ever approved by
the Food and Drug Administration (FDA) in 2004 and by
the Centers for Medicare & Medicaid Services in 2008.
There are now 20 TAH implanting centers in Europe, 15
TAH implanting centers in the United States, and 1 TAH
implanting center in Australia. An additional 18 centers in
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Xof credentialing. The increase in activity has been based on
several factors, including the availability this year in Europe
and Australia of a 6-kg driver that permits hospital dis-
charge. Before that, the majority of implants in the world
were supported by 36 large 180-kg consoles. There were
no other drivers. Patients have now spent more than
20,000 days out of hospital with the SynCardia TAH-t,
and 1 patient surviving as an outpatient for 1327 days re-
cently underwent successful transplantation.
Another factor that may be responsible for the increased
number of implants has been recognition of the limitations
of left ventricular assist device (LVAD) therapy. Recent
publications establish the predictive value of risk scales
such as the Lietz–Miller Score,4 SOFA score,5 HeartMate
II risk score,6 right ventricular failure score,7 and Muenster
score.8 These scores have shown that patients with Inter-
agency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) profile 1, ‘‘crash and burn,’’9
may have a several-fold increased risk with LVADs. In the
multicenter trial with the SynCardia TAH-t,10 we analyzed
43 prognostic factors by univariate and multivariate analy-
ses and compared these with multivariate analyses for
LVADs and biventricular assist devices (BiVADs). We
found that a history of smoking and a prothrombin time
greater than 16 seconds were the only predictors of a bad
outcome for TAH-t recipients at any time postoperatively.11
Factors that had been found to be predictors of mortality
with LVADs in the risk factor scoring systems included
thrombocytopenia, ventilator support, renal dysfunction,rdiovascular Surgery c Volume 143, Number 3 727
Abbreviations and Acronyms
BiVAD ¼ biventricular assist device
BSA ¼ body surface area
ECMO ¼ extracorporeal membrane
oxygenation
FDA ¼ Food and Drug Administration
INTERMACS ¼ Interagency Registry for
Mechanically Assisted
Circulatory Support
LVAD ¼ left ventricular assist device
NYHA ¼ New York Heart Association
PTFE ¼ polytetrafluoroethylene
TAH ¼ total artificial heart
TAH-t ¼ temporary total artificial heart
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Xhepatic dysfunction, previous surgery, and right-sided heart
failure.4-8 These were not significant predictors for the
TAH. A previously published comparative study from our
center documented survival to transplantation of 75% for
TAH recipients, 57% for LVAD recipients, and 38% for
BiVAD recipients.12 The working hypothesis is that the
TAH rescues patients who would have a higher risk with
an LVAD.
Finally, some situations seem best suited for TAH, in-
cluding failed cardiac transplantation (acute or chronic),
massive myocardial infarction, acquired ventricular septal
defect, diffuse mural thrombosis, failed Fontan, severe hy-
pertrophic cardiomyopathy, and catastrophic intraoperative
cardiac damage.
Three programs have implanted more than 100 TAHs in
patients: La Pitie Salpetrier has implanted more than 200
TAHs,13 BadOyenhausen (L. Arusoglu,MD, personal com-
munication, October 2011) has implanted more than 100
TAHs, and our program has implanted more than 100
TAHs. Another source of data on TAH results is available
from INTERMACS,14 but at this early stage of enrollment
into the registry it may be biased by the large number of re-
cent start-up programs in the United States and by the learn-
ing curve effect, particularly with respect to patient
selection. This has not been true in all new programs, for
instance, the Virginia Commonwealth University has
a series of 27 consecutive TAH survivals to transplantation
(M. Hess, MD, and V. Kasirajan, MD, personal communica-
tion, October 2011).
Our series started in 1985 with the Jarvik-7 and in 1993
with the SynCardia TAH-t in an investigational device ex-
emption study aimed at obtaining FDA approval. The Syn-
Cardia TAH-t history, use, sizing, function, indications, and
anticoagulation, and our previous results up to 55 implants
have been reported.15-17 We present the experience with the
SynCardia TAH-t from 1993 to 2009.728 The Journal of Thoracic and Cardiovascular SurgMATERIALS AND METHODS
The current study began in January 1993 and ended in December 2009.
It includes 101 consecutive patients from University Medical Center (Tuc-
son, Ariz), with 65 patients previously reported as part of a multi-
institutional investigational device exemption study from 1993 to 2002.10
Thirty-six more patients from University Medical Center were added be-
tween 2002 and 2009. Indications and exclusions for implantation in that
study have been reported.10 Inclusion criteria were as follows: patient eli-
gible for cardiac transplantation, New York Heart Association (NYHA)
functional class IV, body surface area (BSA) 1.7 to 2.5 m2 or T10 distance
from sternum to anterior vertebral body by computed tomography scan of
10 cm or greater, either cardiac index of 2 L/min/m2 or less and systolic
pressure 90 mm Hg or less and central venous pressure 18 mmHg or
more, or on 2 of the following: dopamine 10 mg/kg/min or greater, dobut-
amine 10 mg/kg/min or greater, epinephrine 2 mg/kg/min or greater, other
drugs at maximum levels, intra-aortic balloon pump, or cardiopulmonary
bypass. Exclusion criteria were as follows: use of any ventricular assist de-
vice, pulmonary vascular resistance of 8 Wood units or greater (640 dynes/
sec/cm5), dialysis in previous 7 days, serum creatinine 5 mg/dL or greater,
cirrhosis with total bilirubin 5 mg/dL or greater, and cytotoxic antibody
10% or greater. After the completion of that study, we liberalized our cri-
teria, accepting some patients for implantation who were too sick to meet
the ‘‘eligible for cardiac transplantation’’ criteria.
A polytetrafluoroethylene (PTFE) neopericardium was constructed to
cover the TAH in 70 of these patients.18 The rationale was to facilitate
explantation. The implantation technique has been reported.19 The same
anticoagulation strategy, including multiple tests and combined anticoagu-
lation and antiaggregant therapies, was used in all patients.16
Adverse events were defined according to the FDA investigational de-
vice exemption trial10 and have been published.20 They are essentially
the same as those published by INTERMACS.21 The definitions of some
of the events were broad. For instance, ‘‘bleeding’’ included perioperative
use of 8 units or more of packed red blood cells, any reoperation for bleed-
ing, any postoperative thoracic drainage of more than 200 mL/h 4 hours or
more postoperatively, and any transfusion of 3 units or more of blood
within a 24-hour period after the first 48 postoperative hours. Neurologic
events included any transient ischemic attack, cerebral vascular event or
seizure, any abnormal cerebral imaging study, and any other cause of neu-
rologic deficit (eg, ischemic damage from cardiac arrest). Stroke is defined
as a neurologic deficit lasting more than 24 hours. Infection is defined as
a positive culture or clinical sepsis with negative culture. Infections were
defined as serious if they were related to death or delayed transplantation.RESULTS
This institutional review board–approved study began in
1993 with our first transplant of the SynCardia TAH-t,
called the ‘‘CardioWest TAH.’’ The last patient included
in the series underwent transplantation in December 2009.
The longest-term survivor is currently alive 16.4 years post-
implantation. All transplantations were performed at the
University Medical Center in Tucson, Arizona. Demo-
graphics are shown in Table 1. There were 101 patients
with a mean age of 48 years (median, 52 years; range,
14–70 years). Eighty-five percent were male, and 75%
were white. Patients had an average weight of 86 kg and
a BSA of 2.05 m2. Nine patients had a BSA of 1.77 m2 or
less. Forty-one patients were on mechanical ventilation,
26 patients were on mechanical circulatory support, 26 pa-
tients had experienced a recent cardiac arrest, and 4 patients
were on extracorporeal membrane oxygenation. SynCardiaery c March 2012
TABLE 1. Demographics and baseline characteristics
All patients (N ¼ 101)
Age at implant (y)
n 101
Mean (SD) 48.5 (12.56)
Median 52.0
Min, Max 14, 70
Gender
Male 86 (85.1%)
Female 15 (14.9%)
Ethnicity
African American 5 (5.0%)
White 76 (75.2%)
Hispanic 18 (17.8%)
Native American 2 (2.0%)
NYHA class
IV 94 (93.1%)
N/A 1 (1.0%)
Missing 6 (5.9%)
INTERMACS status
1 64 (63.4%)
1A 28 (27.7%)
2 7 (6.9%)
2A 2 (2.0%)
Inotropes
Yes 94 (93.1%)
No 3 (3.0%)
Missing 4 (4.0%)
Weight (kg)
n 89
Mean (SD) 85.76 (14.47)
Median 88.00
Min, Max 53.0, 118.6
Height (cm)
n 88
Mean (SD) 177.23 (8.80)
Median 178.50
Min, Max 152.4, 195.0
BSA m2
n 93
Mean (SD) 2.05 (0.20)
Median 2.08
Min, Max 1.6, 2.5
Systolic blood pressure
n 79
Mean (SD) 93.4 (16.18)
Median 92.0
Min, Max 58, 142
Diastolic blood pressure
n 78
Mean (SD) 56.8 (9.34)
Median 55.0
Min, Max 36, 83
Sodium
n 96
Mean (SD) 130.8 (5.92)
Median 131.0
(Continued)
TABLE 1. Continued
All patients (N ¼ 101)
Min, Max 115, 152
Creatinine
n 98
Mean (SD) 1.71 (0.80)
Median 1.60
Min, Max 0.4, 4.5
Total bilirubin
n 91
Mean (SD) 2.02 (1.19)
Median 1.60
Min, Max 0.4, 6.5
BNP
n 8
Mean (SD) 1947.9 (1292.61)
Median 1874.0
Min, Max 91, 3606
Albumin
n 72
Mean (SD) 3.19 (0.60)
Median 3.10
Min, Max 1.8, 4.5
Pre-albumin
n 11
Mean (SD) 13.63 (5.23)
Median 14.00
Min, Max 6.9, 23.0
Platelets
n 89
Mean (SD) 217.9 (100.57)
Median 198.0
Min, Max 23, 587
Lactate
n 17
Mean (SD) 2.31 (2.16)
Median 1.90
Min, Max 0.8, 10.0
RA
n 19
Mean (SD) 15.6 (6.02)
Median 14.0
Min, Max 4, 26
PCWP
n 69
Mean (SD) 30.8 (8.90)
Median 30.0
Min, Max 4, 54
Cardiac index
n 71
Mean (SD) 1.90 (0.48)
Median 1.80
Min, Max 0.9, 3.0
NYHA, New York Heart Association; INTERMACS, Interagency Registry for
Mechanically Assisted Circulatory Support; BSA, body surface area; PCWP, pulmo-
nary capillary wedge pressure; SD, standard deviation; BNP, B-type natriuretic pep-
tide; RA, right atrium; N/A, not available.
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TABLE 2. Adverse events during 24 patient years of support in 101
patients
Adverse event No. (%) Timing postimplantation
Neurologic
Total 16 (15.8%)
Stroke 8 (7.9%) 5 events by 9 d, 3 events thereafter
(0.125 strokes/patient year
after the first 9 d)
No event 85 (84.2%)
Bleeding
Total 43 (42.6%)
Reoperations 25 (24.7%) 11 in first 24 h, mean time to
take-back 4.2 d (range, 0–25)
No event 58 (57.4%)
Infection
Total 64 (63.4%) 50% of infections were in the first
30 d
No event 37 (36.6%)
Peripheral emboli
Total 8 (7.9%) 3 at<7 d, 5 at 38–286 d
No event 93 (92%)
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XTAH-t outputs were 7 to 9 L/min with central venous pres-
sures of 10 mm Hg or less. At explantation, we found that
the PTFE neopericardium decreased adhesion formation
and the ‘‘skin to recannulation time’’ at explantation to 15
to 45 minutes.
Preimplantation, 93% of patients were in NYHA func-
tional class IV. Among the remaining 7 patients, an
NYHA classification was not found on chart review, but
on review of their records we found that all were rapidly de-
teriorating with 6 patients on multiple inotropes and in mul-
tiple organ failure and 1 patient with catastrophic cardiac
damage during a reoperation for endocarditis of an infected
aortic root conduit. Ninety-one percent of patients were IN-
TERMACS profile 1 (crash and burn), 64% of patients were
INTERMACS profile 1, and 28% of patients were INTER-
MACS profile 1A (‘‘A’’ signifies additional risk from ven-
tricular tachycardia or ventricular fibrillation). Among the
other 9 patients, 2 were INTERMACS profile 2A and 7
were INTERMACS profile 2. Therewere 5 ischemic cardio-
myopathies and 1 restrictive and 1 congenital post-Fontan
and Blalock–Taussig shunt. All patients were failing on
high-dose inotropes, but none had high-dose pressor agents.
Ninety-three percent of patients were receiving inotropes. In
the 7 patients who were not receiving inotropes, 4 had cath-
eterizationor acute infarction emergencies (1with a ruptured
left ventricle), 1 had an unrepairable aortic root failure to
wean from cardiopulmonary bypass, and 2 were chronic
cardiac transplant recipients with advanced coronary vas-
culopathy, ischemic cardiomyopathy, and progressive
unresponsive congestive heart failure. Other preimplant var-
iables were similar to those previously reported.10,12730 The Journal of Thoracic and Cardiovascular SurgAdverse events are listed in Table 2. Neurologic compli-
cations were seen in 16 patients (15.8%), and 8 of these
were embolic events (7.9%). Among these, 5 occurred by
day 9. The remaining 3 events were on days 77, 150, and
204. Thus, during the 24 patient years of support, only 3
strokes were seen while patients were on chronic support
and chronic anticoagulation (0.125 events per patient
year). Four patients experienced chronic deficits, and 4 pa-
tients had resolution of symptoms and no neurologic resid-
ual. The other complications included the incidental finding
of lesions on head computed tomography scans with no
known associated symptom in 3 patients, ischemic damage
from cardiac arrest in 2 patients, transient ischemic attacks
in 2 patients, and 1 episode of severe air embolism. Eighty-
five patients (84.2%) had no neurologic complication of
any kind. Among the 8 patients with embolic strokes, 3
had notable infections; 1 died of sepsis on the fifth postim-
plant day, 1 had a protracted bout of mediastinitis involving
the prosthetic ventricles and requiring open chest therapy,
and 1 had an infected inlet valve of the left ventricle that
led to a device change after 11 months.
A broad definition of ‘‘bleeding’’ resulted in the complica-
tion being noted in 43 patients (42.6%). There were 25
mediastinal explorations (24.7%) for hemorrhage. Eleven
take-backs were in the first 24 hours postimplant, the remain-
der werewithin 25 days (mean, 4.2 days; range, 0–25 days for
all tack-backs). Eleven of these ‘‘take-back’’ cases (44%)
died within 5 days to 1 month after implantation. Eighteen
other patients met the definition of bleeding, including 6 by
virtue of the quantity and timing of blood transfusions, 4
from gastrointestinal bleeding, and the remaining 8 from var-
ious other bleeding sites (ie, epistaxis, vitreous, hemothorax,
intracranial, and pericardial). Fifty-eight patients had no
bleeding complication.
Sixty-four patients (63.4%) had infections that were
treated. The lungs and urinary tract were the most common
sites. Three patients had clinical mediastinitis. One patient
survived long term to transplantation after reoperation, de-
bridement, and irrigation and is still alive 4 years later.
The other 2 patients died; one of these patients was a young
postpartum patient with cardiomyopathy who had failed on
Thoratec BiVAD support (Thoratec Corp, Pleasanton, Calif)
and was switched to the TAH, and the other patient had
a massive hemorrhagic myocardial infarction with Crohn’s
disease sent with an intra-aortic balloon pump who had sig-
nificant postimplantation bleeding and developed Proteus
mirabilismediastinitis. One patient had device endocarditis
with methicillin-resistant Staphylococcus aureus. He sur-
vived and was hemodynamically and otherwise stable after
TAH change-out. Support was withdrawn because he had
experienced multiple strokes. One other notable infection
was hemorrhagic Clostridium difficile colitis and sepsis
that resolved after medical treatment with intravenousery c March 2012
FIGURE 1. Survival to transplant is defined as time in weeks from date of device implantation to death before heart transplant. Patients are censored at the
time of transplantation if they are still alive (circles).
Copeland et al Cardiothoracic Transplantationmetronidazole (Flagyl; Pfizer, Inc, NewYork,NY), oral van-
comycin, and vancomycin enemas.
Peripheral emboli were documented in 8 patients in the
following locations: celiac artery (1), spleen (2), superior
mesenteric artery (1), kidney (2), and retina (2). Among
the 6 patients with visceral emboli, 4 died. Four of these
events were in the first week postimplantation.
Two patients died as the result of catheter entrapment of
a central line in the tricuspid valve; 1 patient had a periph-
erally inserted central catheter line, and 1 patient had
a central venous internal jugular line. In both cases, the
end result was irreversible brain damage from device
arrest.
Mean support time was 87  94.8 days (median of 53
days, minimum of 1 day, maximum of 441 days). Survival
to transplantation (the proportion surviving for a given
time while awaiting transplantation) is shown in Figure 1.
Sixty-nine patients (68.3%) survived to transplantation.
Post-transplant survival for the 69 patients who survivedFIGURE 2. Post-transplant survival is defined as time in years from date of t
included in this figure. Censored patients (circles). Patients still alive are censo
The Journal of Thoracic and Cato transplantation is shown in Figure 2. Time zero is the ex-
plant–transplant operation. One-year survival was 76.8%,
and 5-year survival was 60.5%. At the 10-year survival
mark, 41.2% were alive (18 patients). Overall survival re-
fers to the fate of all patients who received implants. The
overall survival at 1, 5, 10, and 15 years was 55.4% (56 pa-
tients), 42.6% (35 patients), 28.1% (18 patients), and
26.1% (3 patients), respectively.
There were 32 deaths on device support. The competing
outcomes analysis graph (Figure 3) demonstrates that
70% of the deaths were in the first 14 days and 90% were
within 40 days after implantation, with 3 additional deaths
over the next 231 days. Causes of death were multiple organ
failure (13), pneumonia or pulmonary edema (6), sepsis (5),
neurologic injury (4, including 1 stroke, 1 hypoxic damage
from hypotension, and 2 intracranial hemorrhage), pancre-
atic abscess (1), small intestinal ischemia (1), disseminated
intravascular coagulopathy (1), and disseminated coccidioi-
domycosis (1).ransplant to death. Only patients who have received a heart transplant are
red as of March 1, 2011.
rdiovascular Surgery c Volume 143, Number 3 731
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FIGURE 3. Competing outcomes analysis for total artificial heart in 101 patients.
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As documented in this study, the TAH controls the circu-
lation on the right and left sides, decreasing the central ve-
nous pressure, increasing the systemic pressure, and
providing a cardiac output (7–9 L/min). The TAH weighs
160 g and displaces 400 mL, and thus fits most adults
with dilated hearts. Explantation is facilitated by creation
of a neopericardium of PTFE at the time of implantation.17
Undisputed indications include failed cardiac transplanta-
tion, acute or chronic, massive myocardial infarction, ac-
quired ventricular septal defect, diffuse mural thrombosis,
failed Fontan, severe hypertrophic cardiomyopathy, and
catastrophic intraoperative cardiac damage.
Other indications, such as severity of illness, rapidity of
decompensation, inadequacy of medical therapies to stabi-
lize the patient, and extent of multiorgan dysfunction, are
continuous variables that create controversy and debate.
Many arguments are made about the survival of the patient,
such as finances, quality of life, medical therapy for device,
assumed device durability, device-specific complications,
and donor heart availability. In the end, we believe that sav-
ing the patient, especially when he/she is mortally ill, is
most important. Further, we believe that our experience
documents the salvage of patients who are outside of the
therapeutic range of LVADs as defined by currently used
risk prediction scores.4-8 This hypothesis is supported by
a report comparing multivariate analysis of risk factors for
other devices with the TAH.11 It is also supported by a study
comparing outcomes with the TAH, LVAD, and BiVAD.12
Continuous-flow devices have now replaced pulsatile
LVADs,22 and registry information is accumulating. More732 The Journal of Thoracic and Cardiovascular Surgsupport for our hypothesis may be found in a recent review
of the INTERMACSRegistry.14 For primary LVAD implan-
tation, it documents independent risk factors, including
older age, higher bilirubin, higher right atrial pressure,
and cardiogenic shock. Further, the authors found that the
percentage of patients with INTERMACS 1 profile who
are treated with LVADs is decreasing. They concluded
that, ‘‘This likely reflects a recognition of the higher early
mortality associated with implementation of mechanical
circulatory support (LVADs) in the throes of cardiogenic
shock.’’
Risk stratification and comparison of independent risk
factors are indirect evidence of efficacy. More direct evi-
dence does not exist. However, on the basis of current infor-
mation, there is a legitimate place for the TAH use in crash
and burn cases and it is the device of choice for some
patients.
There is no doubt about the severity of illness in the
patients in this study. NYHA functional status was IV,
INTERMACS profile was 1 or 1A, and use of inotropes was
universal. Another marker for degree of illness is that most
of the postimplant deaths were early. A number of these pa-
tients were too sick for the TAH. A sicker group has not
been defined. Yet, the survival numbers are reasonable.
Sixty-eight percent of patients have survived to transplanta-
tion, and 77% survived post-transplantation. In a previous
study, matched historical controls all died or underwent
transplantationwithin 7weeks.10Also in that study, which in-
cluded 65 patients from our center, the survival to transplan-
tation was 80%with the TAH. Selection criteria were strictly
enforced, and ‘‘compassionate use’’ cases were censored.ery c March 2012
Copeland et al Cardiothoracic TransplantationAccruing 36more patients over the period from 2003 to 2009
and including all patients from the FDA study have reduced
survival to transplantation by 12%, perhaps because we
have not censored any patients. Thus, this report is a true ac-
counting of all consecutive patients from 1993 to 2009.
One limitation of chart review databases such as ours is
that they rely on written documentation; consequently,
a few patients are not classified by functional status, not
all have preimplant hemodynamic monitoring, and many
do not have adequate data for calculating risk using one of
the many scales.4-8 Another limitation is that emergencies
often limit preimplant data acquisition.
Contraindications for implantation included chronic car-
diac cachexia, advanced physiologic age, chronic failure of
end organs incompatible with recovery, anticipated to be
impossible to recover to transplant candidate status, and
judged to have inadequate mediastinal size for the TAH.
Adverse events, including stroke in 8%, reoperation in
24.7%, device infection in 2.9%, and peripheral embolism
in 7.9%, were serious but acceptable in a group of critically
ill patients. Causes of death on device support were not sur-
prising with most secondary to multiple organ failure (13).
Other causes included pneumonia (6), sepsis (5), and neuro-
logic (4).CONCLUSIONS
There is a real clinical need for TAH support to rescue se-
lect patients with INTERMACS 1 profile from advanced
life-threatening cardiac failure. There are also a number
of specific scenarios that can best be treated with a TAH.
The option for out-of-hospital care decreases cost, improves
quality of life, and provides a long-term support option.
None of the patients in this study were on outpatient device
support. However, as more portable consoles become avail-
able and more centers are trained, the financial burden of
obligatory inpatient care will be removed and more patients
will be able to receive this therapy. From this single-center
inpatient experience, we expect that more lives will be
saved in the future.T
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Dr Hari Mallidi (Stanford, Calif). When you boil the study
down to its essence, it is basically a case series of poor quality
from an epidemiologic standpoint in terms of guiding further fu-
ture therapy, but it is a case series of approximately 100 patients
treated with INTERMACS class 1 status treated with TAH over
a period of 15 to 20 years. The devil is really in the details,
and unfortunately the details were not really provided in the
talk or the article.
There are really no data presented to convince the reader that
in fact these patients are not eligible for LVAD. Do you have
data concerning right ventricular function, pulmonary artery
pressure, right ventricular systolic work index, or any sort of
measure of right ventricular function or dysfunction at the time
of implant?
Dr Hannah Copeland. We do. We looked at all the pressures
and in our article referred to all of those publications. These data
have been reported by Copeland and colleagues.10 Right atrial
pressure was 20 mm Hg, pulmonary artery systolic pressure was
55 mm Hg, mean pressure was 44 mm Hg, and wedge pressure
was 30 mm Hg. There was no difference in this current experience
from that previously published. Further, as noted in the article, ofrdiovascular Surgery c Volume 143, Number 3 733
Cardiothoracic Transplantation Copeland et al
T
X101 patients, 56 were failing on some other form of mechanical
support, had just had a cardiac arrest, or were failing on extracor-
poreal membrane oxygenation (ECMO). We also point out data
from the literature that clearly shows LVAD recipients with multi-
system organ failure have proven not to do well, and this forms the
basis for predictive scales that document poor outcomes in high-
risk LVAD recipients. For instance, a Lietz–Miller score in the
20s predicts a 30% 1-year survival with LVAD support. All of
our patients had multisystem organ failure or pathologic and ana-
tomic reasons for total heart replacement.
Dr Mallidi. In general, our experience has shown that patients
with elevated pulmonary artery pressures for the most part need
LVAD therapy alone. Their right ventricles can be managed with
inotropes or a temporary assist device to removal of the device
or weaning from inotropic therapy with just LVADs.
There is no cohort for comparison. Do you have any data of the
other ventricular assist device recipients at your center with re-
spect to those who just received LVADs or BiVADs but not neces-
sarily a TAH?
Dr H. Copeland. Contemporary experience with other devices
at the same institution was published comparing it with the
TAH.12 Briefly, survival was best with the TAH, followed by
LVAD and then BiVAD. At our institution, more than 350 devices
were implanted, including more than 150 LVADs, 82 BiVADs,
and 15 right ventricular assist devices during the time of our re-
ported TAH series. We did experience a 2-year time period
when the TAH was not available and incurred high mortality rates
attempting to salvage the same patient population with LVADs or
BiVADs.
DrMallidi. There were certain groups of patients in your study
who were not eligible for traditional ventricular assist devices.
These included those with transplant failure, chronic or acute re-
jection, hypertrophic cardiomyopathy, or complex congenital
anomalies. How many patients with the TAH have those indica-
tions for the device versus just the crash and burn case?
Dr H. Copeland. The majority were crash and burn cases.
There were a few failed Fontan operations, 1 peripartum cardio-
myopathy, and several intraoperative cardiac disasters that could
only be resolved with a TAH, and then as previously mentioned
and noted in the article, 26 patients were failing on a device
(mainly LVADS), 26 patients had just experienced cardiac arrests,
and 4 patients were failing ECMO. The rest were emergency
placements.
DrMallidi. The most recent patients with INTERMACS report
class 1 status had an overall survival of approximately 80% at 3
months. There was obviously a difference in survival between
thosewho just received an LVADand thosewho received a BiVAD,
and according to the latest INTERMACS report, the TAH seems to
have a survival in between the BiVAD and LVAD recipients, but
class 1 patients are class 1 patients; they are crash and burn. The
philosophy at many ventricular assist device centers has changed734 The Journal of Thoracic and Cardiovascular Surgfrommaximal support with devices for these patients to immediate
minimally invasive or less-invasive approaches to promote end-or-
gan recovery before a more definitive treatment. During the last 1.5
years at Stanford, we have probably had approximately 15 crash
and burn cases that were managed with temporary percutaneous
devices or ECMO as a bridge to another device. What we found
is 3 patients did not survive. Of the remaining 12, only 6 actually
ended up receiving a ventricular assist device of any kind, and of
those 6 only 2 ended up with a temporary right ventricular assist
device and the rest just had LVAD therapy. This experience is prob-
ably being recapitulated at many other centers. What this study
represents is a philosophy that has fallen out of favor at many cen-
ters in terms of the sicker the patient the greater the support that
needs to be administered immediately.
Dr H. Copeland. The INTERMACS database, as mentioned in
our article, for the TAH reflects the learning curve because a large
number of centers are starting their TAH experience, and often pa-
tient selection in this situation focuses on patients who we would
categorize as ‘‘compassionate need.’’ Therefore, I disagree with
your comment first of all.
In regard to how far you want to gowith these patients, I will tell
you this. I am a new mother of 6 months, and I am beyond hyper-
vigilant for all of my patients. I have a great respect for life. I
would hope that your comments do not reflect any less respect.
It is unfortunate if they (INTERMACS 1 cases) end up at your
center and you do not treat them and instead send them to hospice.
Using ECMO as a bridge to decision is valid and has been used by
our program many times. ECMO and low-flow (5 L/min) tempo-
rary devices may be inadequate to reverse advanced pathophysiol-
ogy and therefore mislead surgeons and physicians and only serve
as a pathway to patient death.
Dr Joseph Cleveland (Aurora, Colo). This patient population
remains challenging with regard to durable device implantation
and outcomes. We have just published in The Journal of Heart
and Lung Transplantation our analysis of the INTERMACs data-
base looking at BiVAD versus LVAD recipients. The outcomes are
clearly inferior for the BiVAD recipients, and it gets down to again
not the pump but the population. This patient group is extremely
difficult. They are extremely high risk, and I think we need a better
paradigm than implantable durable pumps. This strategy of Bi-
VAD or TAH is just not going to result in good outcomes for
this patient population and in particular for the INTERMACs level
1 cases. Our center has moved away from placing durable pumps
in these patients and toward ECMO or other short-term assist de-
vice strategies. It is incredibly difficult to sometimes walk away
from people, but at the same time we are going to be the group
faced with responsibly using this technology and making sure
that the technology remains viable. We cannot be operating on pa-
tients who are unsalvageable to attempt heroic operations with Bi-
VADs or artificial hearts because the data do not justify this
practice.ery c March 2012
